Kerry Culm-Merdek

Development of a simple and rapid method for producing non‐fucosylated oligomannose containing antibodies with increased effector function

Qun Zhou, Srinivas Shankara, André Roy et al. · Biotechnology and Bioengineering · 2007 · 183 citations

Engineering, Glycobiology, Immunology +19

Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency

Melissa Wasserstein, Simon Jones, Handrean Soran et al. · Molecular Genetics and Metabolism · 2015 · 110 citations · Full text

Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study

Loren Peña, Richard J. Barohn, Barry J. Byrne et al. · Neuromuscular Disorders · 2018 · 89 citations · Full text

Dose Study, Immunodeficiencies, Pharmacotherapy +3

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naval Daver, Pau Montesinos, Daniel J. DeAngelo et al. · Blood · 2019 · 62 citations

Fluvoxamine impairs single‐dose caffeine clearance without altering caffeine pharmacodynamics

Kerry Culm-Merdek, Lisa L. von Moltke, Jerold S. Harmatz et al. · British Journal of Clinical Pharmacology · 2005 · 56 citations · Full text